Year: 2004
Type: article
Abstract: ereditary paraganglioma (PGL) is characterised by slow growing, vascular tumours that can develop in any component of the paraganglia, a neuro-ectodermal system that is distributed from the skull base to the pelvic floor. 1 Common tumour sites include the carotid body in the head and neck and adrenal and extra-adrenal paraganglia in the abdomen.Heterozygous germline inactivating mutations in SDHD, SDHC, and SDHB, which encode three of the four subunits of mitochondrial complex II (succinate dehydrogenase), cause hereditary paraganglioma types 1, 3, and 4 (PGL1, PGL3, and PGL4), respectively.Mutations in the fourth subunit of mitochondrial complex II, SDHA, have yet to be demonstrated in hereditary paraganglioma.Germline loss of function mutations followed by somatic loss of nonmutant alleles in the tumours 2-4 suggests a tumour suppres- sor role for mitochondrial complex II in the paraganglia.Over 25 mutations in SDHD and 25 mutations in SDHB have been detected in hereditary paraganglioma, including those reviewed by Baysal 1 and the more recent additions of multiple mutations in SDHB [4][5][6] and SDHD.[7][8][9] All reported mutations are single nucleotide alterations leading to splice site, missense, nonsense, or frameshift mutations, or intraexonic deletions and insertions of up to four nucleotides, which have been detected through exonic PCR amplifications and sequencing.In contrast to the abundance mutations in SDHB and SDHD, only a single multiply affected family and an isolated case, containing a single nucleotide initiation codon and a splice site mutations in SDHC, respectively, have been described by Niemann et al. 3 10 However, analyses of SDHC in four series of patients with paraganglioma or pheochromocytoma 6 8 11 12 yielded no definitive SDHC muta- tions.These findings indicate that the relative contribution of complex II subunit mutations to hereditary paraganglioma is not similar and may reflect currently unrecognised aspects of complex II biology.Hence, it is of utmost importance that role of SDHC in familial and sporadic paragangliomas be confirmed independently.Penetrance of complex II mutations shows peculiar characteristics.Mutations in SDHD cause PGL1 only if the transmission occurs paternally, whereas maternal transmission does not cause disease, 13 suggesting operation of genomic imprinting on SDHD.In contrast, SDHB mutations are transmitted both paternally 11 and maternally.14 Thus far, transmissions of SDHC mutations causing disease occurred through mothers in the one multiplex family 14 and in one isolated case 10 .Because the molecular basis of the parent of origin effects in PGL1 is unknown, it is unclear whether transmissions of mutations in SDHC, the protein product of which couples with that of SDHD and forms the membrane spanning domain of mitochondrial complex II, also shows any parent of origin effects. METHODSThe family and the isolated cases were ascertained from two US otolaryngology clinics (University of Pittsburgh School of Medicine, Pittsburgh, PA and House Ear Institute, Los Angeles, CA) under research protocols approved by the University Institutional Review Board committee.DNA isolation, genotyping of simple tandem repeat polymorphisms, PCR amplification and sequencing were performed using standard techniques 2 and all simple tandem repeat polymorphisms were amplified in the presence of 10% glycerol and 5% DMSO after labelling one oligonucleotide primer with 32 P and analysed on a 6% polyacrylamide gel.DNA from the multiplex family was isolated either directly from white blood cells or from transformed lymphoblastoid Abbreviations: PGL1, PGL3, and PGL4, hereditary paraganglioma types 1, 3, and 4; PLNA, percentage loss of normal alleles; RA, ratio of alleles; SDH, succinate dehydrogenase Key points N Hereditary paraganglioma (PGL) is characterised by
Source: Journal of Medical Genetics
Authors: B E Baysal, J E Willett-Brozick, P A A Filho, E C Lawrence, E N Myers, R E Ferrell
Institution: University of Pittsburgh
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: British Heart Foundation
OpenAlex ID: W2151611398
